Protein binding and pharmacokinetics of cholesterol-modified heteroduplex oligonucleotides (IMAGE)

Tokyo University of Science

Protein binding and pharmacokinetics of cholesterol-modified heteroduplex oligonucleotides

Caption

This study revealed that, by binding to lipoproteins, cholesterol-conjugated heteroduplex oligonucleotides (Chol-HDOs) can remain in the bloodstream for longer and reach brain tissue much more effectively than their antisense oligonucleotide (ASO) counterparts. These findings pave the way for the development of gene-modulating drugs targeting the brain.

Credit

Makiya Nishikawa from Tokyo University of Science, Japan

Usage Restrictions

Cannot be reused without permission.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.